Page 11 - Uro_Onco_booklet

Local Experience on PSA Flare Observed in Patients on
Abiraterone
• PSA flare can be defined as an initial rise in serum PSA under therapy,
followed by a drop to values below baseline. 1
• But PSA flare does not necessarily cause clinically relevant issues. 1,2
3
• As per a local study, over 50% of mCRPC patients on abiraterone
with initial PSA flare had ultimate PSA response to abiraterone. No
substantial difference in clinical outcomes in patients with or without
PSA flare.
• As long as patients are not clinically deteriorating, a temporary PSA
increase during initial systemic treatment should be monitored for
a sufficient period (i.e. 3 months) to avoid early withdrawal from
treatment in the absence of genuine disease progression.

Conclusion
 The consensus statements were derived from recent clinical
evidence and major overseas guidelines, with the
consideration of local clinical experience and practicability.

 These are considered applicable recommendations for Hong
Kong physicians for the management of mPC patients.
 These statements and physicians’ practice are subject to
regular review and necessary updating.

Note: To formulate the consensus statements, the panel reviewed the literature published from Jan
2005 to Aug 2016.

References: 1. Olbert PJ, et al. Anticancer Drugs 2006; 17: 993-6. 2. Burgio SL, et al. Clin Genitourin Cancer
2015; 13: 39-43. 3. Poon DM, et al. BMC Urol 2016; 16: 12.
11